The Latest Breaking News from CME Group

In May, an eccentric 30-year-old cryptocurrency billionaire named Sam Bankman-Fried made a startling proclamation. In a podcast interview, Bankman-Fried said he would spend as much as $1 billion of his estimated $12.8-billion fortune on American politics by the 2024 election, joining the ranks of megadonors such as George Soros and…

A whale with a lot of money to spend has taken a noticeably bullish stance on CME Group. Looking at options history for CME Group (NASDAQ:CME) we detected 12 strange trades.

 

Over the past 3 months, 12 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

If history is any guide, there may be trouble ahead for shares of CME Group (NASDAQ:CME). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

A group is seeking regulatory approval for the Intelligent Medicine Exchange, which could help participants hedge risks from rising medical costs.

CME Group (NASDAQ:CME) has outperformed the market over the past 10 years by 2.35% on an annualized basis producing an average annual return of 14.45%. Currently, CME Group has a market capitalization of $71.41 billion.

Upgrades Credit Suisse upgraded the previous rating for Molecular Partners AG (NASDAQ:MOLN) from Underperform to Neutral. NoneAt the moment, the stock has a 52-week-high of $32.04 and a 52-week-low of $5.92. Molecular Partners closed at $6.88 at the end of the last trading period.

Over the past 3 months, 11 analysts have published their opinion on CME Group (NASDAQ:CME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.